Nebacumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | endotoxin |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| KEGG | |
  (what is this?) (verify) | |
Nebacumab is a human monoclonal antibody developed for the treatment of sepsis.[1] It has been withdrawn in 1993 because it failed to reduce mortality in clinical trials.[2]
References
- ↑ Derkx, B.; Wittes, J.; McCloskey, R. (1999). "Randomized, Placebo‐Controlled Trial of HA‐1A, a Human Monoclonal Antibody to Endotoxin, in Children with Meningococcal Septic Shock". Clinical Infectious Diseases. 28 (4): 770–7. PMID 10825037. doi:10.1086/515184.
- ↑ WHO: Consolidated List of Products
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.